Method
Level · gp.fundamentals.debt_to_revenue
Raw value 128.50% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTINSMED Inc's latest supported as-filed period reports revenue of $425.5M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 128.50% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 1.47% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -20.88% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 296.11% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 33.46% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -0.36% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -57.6% from the comparable as-filed period. The change ranks at the 73th percentile of 215 prior comparable changes.
Debt changed +0.0% from the comparable as-filed period. The change ranks at the 33th percentile of 57 prior comparable changes.
Inventory changed +32.3% from the comparable as-filed period. The change ranks at the 55th percentile of 51 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
INSM · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001182633-26-000010SEC ↗4Aug 12, 2026Period Aug 10, 20260001685904-26-000014SEC ↗4Aug 7, 2026Period Aug 6, 20260001796960-26-000020SEC ↗8-KAug 6, 2026Period Aug 6, 20260001140361-26-031502SEC ↗10-QAug 6, 2026Period Jun 30, 20260001104506-26-000041SEC ↗4Jul 24, 2026Period Jul 23, 20260001402051-26-000042SEC ↗8-KJul 16, 2026Period Jul 16, 20260001140361-26-028602SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 17, 2026Filed Aug 19, 2026 | SHAROKY MELVIN MDDirector | Open Market SaleIndirect | 5,000 | $128 | $637,650 | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 82,280 | $14 | $1.1M | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 76,600 | $17 | $1.3M | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 80,970 | $30 | $2.5M | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 49.36% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 9.70% · OPTIONAL
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Net income changed +95.9% from the comparable as-filed period. The change ranks at the 94th percentile of 108 prior comparable changes.
Operating income changed +99.5% from the comparable as-filed period. The change ranks at the 94th percentile of 126 prior comparable changes.
Operating margin changed +29091 basis points from the comparable as-filed period. The change ranks at the 88th percentile of 58 prior comparable changes.
Research & development changed +18.5% from the comparable as-filed period. The change ranks at the 29th percentile of 126 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001402051-26-000040| Adsett RogerChief Operating Officer |
| Open Market SaleDirect |
| 239,850 |
| $133 |
| $32.0M |
| Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 82,280 | $0 | $0 | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 76,600 | $0 | $0 | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 80,970 | $0 | $0 | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Option ExerciseDirect | 18,278 | $19 | $346,368 | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Option ExerciseDirect | 8,895 | $26 | $229,758 | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Open Market SaleDirect | 8,895 | $127 | $1.1M | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Open Market SaleDirect | 18,278 | $129 | $2.4M | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Option ExerciseDirect | 18,278 | $0 | $0 | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Option ExerciseDirect | 8,895 | $0 | $0 | Form 4 ↗ |
| Jul 23, 2026Filed Jul 24, 2026 | Lewis WilliamChair and CEO | Option ExerciseDirect | 6,260 | $30 | $190,680 | Form 4 ↗ |
| Jul 23, 2026Filed Jul 24, 2026 | Lewis WilliamChair and CEO | Option ExerciseDirect | 4,440 | $17 | $76,190 | Form 4 ↗ |
| Jul 23, 2026Filed Jul 24, 2026 | Lewis WilliamChair and CEO | Open Market SaleDirect | 4,828 | $106 | $509,933 | Form 4 ↗ |
| Jul 23, 2026Filed Jul 24, 2026 | Lewis WilliamChair and CEO | Open Market SaleDirect | 5,872 | $106 | $624,957 | Form 4 ↗ |
| Jul 23, 2026Filed Jul 24, 2026 | Lewis WilliamChair and CEO | Option ExerciseDirect | 6,260 | $0 | $0 | Form 4 ↗ |
| Jul 23, 2026Filed Jul 24, 2026 | Lewis WilliamChair and CEO | Option ExerciseDirect | 4,440 | $0 | $0 | Form 4 ↗ |